Myriad Genetics Inc
(FRA:MYD)
€
13
-0.1 (-0.76%)
Market Cap: 1.21 Bil
Enterprise Value: 1.25 Bil
PE Ratio: 0
PB Ratio: 1.70
GF Score: 72/100 Myriad Genetics Inc at Bank of America Healthcare Conference Transcript
May 11, 2022 / 06:20PM GMT
Release Date Price:
€18.78
(+0.97%)
Derik De Bruin
BofA Securities, Research Division - MD of Equity Research
Welcome to Bank of America's 2022 Healthcare Conference live from Las Vegas. I'm Derik De Bruin, the senior life sciences and diagnostic tools analyst. And our next company is Myriad Genetics. And with us from Myriad is Paul Diaz, President and CEO. Paul, welcome. Thanks for being here.
Paul J. Diaz
Myriad Genetics, Inc. - CEO, President & Director
Great to be here. Thanks for the invitation.
Questions & Answers
Derik De Bruin
BofA Securities, Research Division - MD of Equity Research
So Paul just to -- you're 2 years into the CEO role?
Paul J. Diaz
Myriad Genetics, Inc. - CEO, President & Director
Not quite.
Derik De Bruin
BofA Securities, Research Division - MD of Equity Research
Not quite 2 years in, yes. And I first picked up coverage of Myriad in 2001, right? So I've got -- been looking at this going to be a long time. I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot